Overview

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Gemcitabine
Paclitaxel